

Becas  GILEAD
a la Investigación Biomédica

2026 CALL:

Reception of proposals through the website: www.BecasGileadInvestigacion.es from 1 to 30 June 2026.

Language of Project presentation (page 11): All information submitted for evaluation must be submitted in English (research project report and CV of the researchers).

Beneficiaries Requirements (page 4): Non-profit organizations and entities benefiting from patronage listed in articles 2 and 16 of Law 49/2002 of 23 December and Health Research Institutes and Public Research Consortia that are members of Public Research Organisations in the field of health sciences.

Type of projects (page 5): National research programmes in the areas of HIV, Haematology-oncology and Medical Oncology research, which have an execution period of no more than 24 months and are carried out in Spanish Health Care Centres.

Type of categories of research groups (p. 5):

- Groups led by researchers born in 1986 or later.
- Groups led by researchers born before 1986.

Exclusion of Projects (page 5): Among other aspects, the following projects will be excluded:

- That evaluate drugs marketed or in the process of development, regardless of whether they are drugs owned by GILEAD, another pharmaceutical company or another entity, organization or academic institution.
- Presented by a researcher who had been part of the research team of a project that obtained a grant in the previous year's call.
- Presented by a researcher who was pending the delivery of the scientific and/or economic report of the closing of a Gilead grant that has already ended.

Maximum number of projects to be submitted (page 12): A maximum of two projects may be submitted **per therapeutic area and health care centre**. A health care centre will be understood as the one to which the principal investigator of the project is attached.

Each principal investigator may only submit one Research Project proposal (p. 12).

Validation of the applications received (page 13): The first week of July, it will be verified that the applications submitted meet the requirements established by the Bases of the call. If it does not comply with the Bases, the applicant will be notified, and a period of 10 calendar days will be opened.

Evaluation system (p. 13): The evaluation of the projects received will be carried out by the Instituto de Salud Carlos III, which will act independently and in accordance with the principles of transparency, objectivity, and equal treatment.

Maximum number of grants to be granted (page 12): A maximum of one project may only be awarded per therapeutic area and per health care centre. A health care centre will be understood as the one to which the principal investigator of the project is attached.

Two projects will be selected for funding **in the category of "research groups led by researchers born in 1986 or later" (page 5)**, which will be the ones with the highest score regardless of the research area. Subsequently, the rest of the projects will be selected based on the score obtained and the availability of financial endowment according to research area, regardless of the age of the principal investigator.

Budget for the grant (page 10): Variable amount that may not exceed 55,000 euros per project.

This aid will be compatible with obtaining other subsidies, aid, income or resources of a public or private nature.

INTRODUCTION

Considering that the **generation of scientific knowledge** in the field of health sciences, its dissemination and application to healthcare activity is a key element in achieving progress and improving the living conditions of citizens, **GILEAD SCIENCES, S.L.U. (GILEAD) has been actively developing a policy to promote and support for the implementation of projects** research and educational and scientific programs of relevance in therapeutic areas of interest (such as HIV/AIDS, cancer, hemato-oncological and liver diseases and other viral infections), considering that they present care needs that are not yet covered.

Accordingly, GILEAD has announced the **"13th Call for Gilead Grants for Biomedical Research in HIV, Hemato-oncology and Medical Oncology"** with the aim of promoting the development of healthcare research in our country in these areas.

This Call aims to promote the realization of **new research projects** that are beneficial for patients, for our society and, ultimately, for the scientific community, through the granting of monetary contributions for their execution.

This initiative of financial support for the execution of research activities, promoted by GILEAD, is in line with public policies to promote and promote scientific and technical research, especially in the biomedical area, as well as with the aim of boosting collaboration and cooperation between the various agents involved in the health sciences sector (private entities, public research bodies and the National Health System centres themselves), with the aim of **generating synergies between research groups that make it possible to obtain results that can be transferred to the improvement of public health.**

This call coincides with other investment initiatives in R&D applied to health sciences promoted by the Spanish Ministry of Health, Social Services and Equality.

For all these reasons, GILEAD intends, through this initiative, to contribute to the promotion and development of public-private collaboration instruments in the field of healthcare research in the areas of HIV, Hemato-oncology and Medical Oncology.

To this end, an agreement has been signed with the Management of the Instituto de Salud Carlos III to have its participation in the evaluation process of the research projects submitted within the framework of this call, also with the support of the Ministry of Health, Social Services and Equality.

First. - Object

The purpose of these Terms and Conditions are intended to establish the rules, requirements and specifications for GILEAD grants awarded within the framework of the **"13th Call for Gilead Grants for Biomedical Research in HIV, Hemato-oncology and Medical Oncology"**.

These funds will be awarded through a competitive procedure that reviews all applications submitted, under terms that guarantee the principles of publicity, transparency, objectivity, equality and non-discrimination in the grant procedure.

In this competitive procedure, the financial grants are awarded after comparing the applications submitted to establish the priorities thereof, in accordance with the objective review criteria defined in section 2.2 of the Grant Award and Notification document, in which the funds are awarded to the applications with the highest scores (**upper limit of 55,000 euros per project**) until all available financial resources are assigned under the terms described in Condition Four of this call.

The grants awarded will be formalised by signing a Letter of Concession between GILEAD and the beneficiary applicant entity in accordance with the terms provided for in the applicable legislation.

Second. – Grant Beneficiary requirements

1. The grants included in this Call may be granted to those proposals for research projects in national territory that are carried out in Spanish Health Care Centres and that come from the non-profit organisations and entities benefiting from patronage listed in Articles 2 and 16 of Law 49/2002, of 23 December. of the tax regime of non-profit entities and of the tax incentives for patronage and provided that they meet the requirements established in Article 3 of said Law. In particular, and considering the provisions of the aforementioned regulations, as well as the scope of this Call for Aid, the following entities are included:

- Foundations
- Associations declared to be of public utility.
- The federations and associations of the non-profit entities referred to in the preceding paragraphs.
- Public and private universities that meet the above requirements

- The Public Research Bodies dependent on the General Administration of the State.
2. Likewise, the grants can be awarded to health research institutions and to public research consortiums under the auspices of public research agencies in the field of health sciences. In such situations, the legislative or regulatory requirements that are applicable to such institutions shall be considered.
 3. The grants may not be awarded to natural persons, but only to the institutions described above, which must submit the documentation listed in the grant procedure described in the Grant Award and Notification section hereof.
- 4. Projects submitted by a researcher who had been part of the research team of a project that obtained a grant in the previous year's call will be excluded from this Thirteenth Call.**

Third. -Characteristics and categories of research groups

All proposals submitted must fall into one of the following categories of research groups:

- **Groups led by researchers born in 1986 or later**, with a scientific production that allows them to be considered to have the potential to become highly competitive groups, which must present differentiated and innovative proposals for action, which do not involve a fracture of pre-existing groups.
- **Regular groups (led by researchers born before 1986)** that must comply with the general conditions established in the different sections, without any other of a specific nature.

Fourth. - Requirements for Research Project Proposals

A) Research lines allowed

Proposals submitted within the framework of this call may only refer to research projects that take place in the national territory and have an execution period of no more than 24 months. This period will begin to run from the date of signing the Letter of Concession in activities of general interest referred to in the Granting of Aid and Communication section of this website.

The projects must be framed in one of the lines of research defined below:

HIV:

1. Research to improve knowledge in the following populations of people living with HIV (PLWH):

- people over 50 years of age,
- women,
- transgender people,
- migrant population,
- chemsex users,
- sex workers,
- homeless people,
- people with HIV/HBV co-infection

- a. Proposals to improve both epidemiological knowledge and the care cascade of these populations (including immuno-virological aspects, resistance to antiretroviral treatment and adherence to care and antiretroviral treatments).
- b. Proposals to improve clinical management and decision-making with a focus on certain comorbidities in these populations: metabolic alterations, neuropsychiatric comorbidity, cardiovascular comorbidity, frailty and co-infection with the hepatitis B virus.

2. Research into innovative care strategies that reduce the frequency of hospital visits or optimize the use of health system resources.

3. Research proposals that analyze the needs and psychosocial, individual and structural factors that condition the access, non-initiation, adherence or discontinuation (CD) of PrEP in these populations: transgender people, people in prostitution, men who have sex with men (MSM) who are migrants, users of problematic chemsex and people with impulse control disorders. Multicenter proposals will be prioritized.

Strategies with clear indicators, and with the potential for transfer to healthcare practice, will be prioritised.

Proposals for research projects that are not within the lines of research established in these terms and conditions and that directly study drugs or other type of therapies owned by GILEAD, another pharmaceutical company or another academic body or institution will be excluded. Studies that include assessments or comparative evaluations of treatments in their objectives will not be accepted.

Hemato-oncology:

B-origin lymphomas (Diffuse Large B-Cell Lymphoma, Mediastinal Primary B-Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma):

1. Optimization, automation and improvement of operational and administrative processes of the CAR T circuit

Projects aimed at automation and improvement of existing processes, including optimization of circuits and times, and associated administrative processes Examples (but not limited to): automation of reports, establishment/updating of protocols, redesign of workflows, optimization of internal circuits, improvement of traceability/documentation.

2. Optimisation of the diagnosis and evaluation of the candidate to speed up access to CAR T:

Projects aimed at optimizing diagnostic tests and pre-treatment evaluation with a focus on reducing delays and improving circuits. Examples (but not limited to): optimization of diagnostic tests (management of times and circuits), integration and prioritization of tests (imaging, laboratory, etc.), rapid diagnostic routes, coordination of agendas and critical time windows.

3. Identification of candidate patients, and connection between levels of care to improve referral:

Projects to facilitate the identification of candidate patients and strengthen the connection between levels of care, favouring agile and timely referral. Examples (but not limited to): improvement of referral criteria and circuits, screening/warning tools, coordination agreements between centres, support for connections between centres and levels, standardisation of handoffs and referrals.

4. Multidisciplinary coordination, inter-site communication and clinical governance of the patient journey:

Strategies to improve comprehensive management, referral and care coordination, including optimisation of inter-centre communication/coordination, therapeutic committees/discussions, working groups and telematic participation.

5. Innovative technologies and digital solutions (incl. AI) applied to optimize the patient journey:

Projects that incorporate innovative methodologies, including artificial intelligence tools and/or advanced data analysis, aimed at optimizing the care path of the CAR T candidate and/or the efficiency of the process. Examples (but not limited to): models/algorithms for bottleneck detection and circuit optimization, advanced analytics for segmentation and prioritization, intelligent flow automation, digital coordination and tracking tools, data mining, natural language processing (NLP) for extracting variables from unstructured clinical text (e.g., reports, evolutions, pathology), advanced dashboards.

6. Support interventions and optimisation of the patient's general condition (pre-habilitation and accompaniment):

Projects aimed at improving the patient's general condition through support interventions (e.g. nutrition, physiotherapy, psychosocial support, social work, accompaniment programmes).

Proposals for research projects that are not within the lines of research established in these terms and conditions and that directly study drugs or other type of therapies owned by GILEAD, another pharmaceutical company or another academic body or institution will be excluded.

The proposals must focus on the optimisation of the care and organisational path of the CAR T within the hospital environment and the current care model.

Studies that include assessments or comparative evaluations of treatments in their objectives will not be accepted

Medical oncology (solid tumors):

1. Clinical or clinical-translational projects in patients with solid tumours in which innovative applications in oncology of new technologies, such as artificial intelligence, applied to clinical or molecular data, are developed.
2. Clinical or clinical-translational projects in solid tumors related to the study of prognostic variables and predictive variables.
3. Follow-up studies of patient cohorts or case-controls.

Only projects led by a specialist in Medical Oncology will be accepted and it will be valued that the research team is multidisciplinary and includes specialists in Medical Oncology from multiple centers.

Proposals for research projects that are not within the lines of research established in these terms and conditions and that directly study drugs or other type of therapies owned by GILEAD, another pharmaceutical company or another academic body or institution will be excluded. Studies that include assessments or comparative evaluations of treatments in their objectives will not be accepted.

B) Modalities of participation

Research project proposals may be submitted in one of the following modalities:

a) Single-centre study: project requested by a single beneficiary applicant entity in accordance with the provisions of the Second Basis of this call, and which is carried out in a single clinical healthcare centre. Such projects may be subcontracted, and the beneficiary entity must ensure that the subcontracting is carried out in accordance with the applicable legislation and regulations.

b) Multicentre study: project requested by a single beneficiary applicant entity in accordance with the provisions of the Second Base of this call and which is carried out in several clinical healthcare centres. The coordinating centre must communicate the participating centres in the application.

C) Excluded areas

Proposals for research projects that are not within the lines of research established in these terms and conditions and that directly study drugs or other type of therapies owned by GILEAD, another pharmaceutical company or another academic body or institution will be excluded. Studies that include assessments or comparative evaluations of treatments in their objectives will not be accepted.

D) Ethical-legal aspects of research projects

Research projects eligible for grants must respect the fundamental principles established in the Declaration of Helsinki, the Council of Europe Convention on Human Rights and Biomedicine, the UNESCO Universal Declaration on the Human Genome and Human Rights, as well as meet the established requirements in Spanish legislation in the field of medical research, the protection of personal data and bioethics, in accordance with Law 14/2007, of July, on Biomedical Research and the other requirements established in Spanish legislation in this regard.

The projects will comply with the legal and regulatory provisions in force and those that modify or develop them, and specifically:

- a) Projects that involve research on humans or the use of biological samples of human origin must comply with the provisions of Law 14/2007, of 3 July, on Biomedical Research and other current legislation on the subject.
- b) Projects involving clinical trials must comply with the provisions of Royal Decree 1090/2015, of 4 December.
- c) Post-authorisation observational studies with medicinal products for human use in accordance with the provisions of Royal Decree 957/2020, of 3 November.

Fifth. Financial allocation of the aid

The "**13th Call for Gilead Grants for Biomedical Research in HIV, Hemato-oncology and Medical Oncology**" promoted by GILEAD is endowed with € 825,000.00 euros, intended for the financing of research projects that meet the requirements and conditions described in these Bases. Approximately €275,000 will be allocated to the HIV area (40% will be dedicated exclusively to the prevention modality within the HIV section), €110,000 for the Haematology-oncology area and €440,000 for the Medical Oncology area.

After the evaluation of the projects, **the two projects that obtain the highest score for funding, regardless of the research area to which they belong, will be selected from the category of "research groups led by researchers born in 1986 or later" (page 5)**. The rest of the projects will be ordered based on the score obtained in the evaluation and those that have obtained the highest score will be selected for funding until the available economic endowment by research area is exhausted, without taking into account the year of birth of the principal investigator.

The grants granted under this call will take the form of a **monetary contribution** with a variable amount that may not exceed 55,000.00 euros per project and which will include administrative management costs.

This grant will be compatible with obtaining other grants, income or resources of a public or private nature intended to finance the research project presented within the framework of this call, provided that the amount already received, by itself, or in addition to the amount of the grant proposed in this call does not exceed the total cost of the research activity in question. Precisely, for this reason, the granting of the requested aid will take into account the existence of other sources of funding available to the research team of the applicant entity, according to the information provided in the Application Form.

In the project review and review process, the Instituto de Salud Carlos III Review Board shall be entitled to adjust the budget itemization listed in such projects to the standards defined in calls by such institution.

If sufficient funds are freed up due to waiver by one or more of the beneficiaries following a grant award, GILEAD may propose that the grant be awarded to another grant recipient based on the score order obtained in the final reports prepared by the Technical Review Boards, which must accept them under the same terms indicated herein.

Sixth. - Items eligible for grant

Grants awarded hereunder must cover costs directly related to the execution of the activities of the research project submitted by the potential grant recipient, with the scope and limits set forth herein.

However, only activities considered consistent with the specific objective or purpose of the non-profit organization applying for the grant will be considered eligible for funding.

In particular, the following project execution costs are considered eligible for grants:

- a) Cost of depreciation or rental of newly acquired scientific-technical equipment, to the extent and during the period in which it is used for the research project.
- b) Cost of consumables and supplies necessary for the execution of the project.
- c) Costs for contract research.
- d) Travel and subsistence allowances of the members of the research team, duly justified, including visits and stays of researchers provided that they are directly related to the project. Expenses for attending congresses will only be accepted if the attendance is for the dissemination of the project's data.

e) Supplementary overhead costs directly derived from the project or action.

f) Personnel costs directly and exclusively related to the implementation of the subsidised research project (maximum one year).

In no case may the amount of the aid received within the framework of this call be used to directly finance the staff of the research team or teams for their healthcare activities, in such a way that it will be up to the entities, institutions or bodies on which said staff depend professionally to assume the payment of their remuneration. However, it will be possible to remunerate the research team with funds obtained through this call based on the time dedicated exclusively to the project.

Likewise, costs to acquire scientific-technical equipment are also not considered eligible for funding.

GRANTS AWARD AND NOTIFICATION

1. Submission of applications

Applications to take part in this Call must be made online through this website www.BecasGileadInvestigacion.es.

In this Thirteenth Call for Proposals, **all information must be submitted in English (Project Report and CV of the researchers)** and therefore, no projects that are presented in a language other than this one will not be evaluated.

Each **principal investigator may submit only one research project proposal**. A maximum of two projects may be submitted per therapeutic area and healthcare center (Principal Investigator affiliated healthcare center).

Only one project at most may be awarded per therapeutic area and healthcare center (Principal Investigator affiliated healthcare center).

For each application, **the category of research group in which you participate must be indicated** (group led by researchers born in 1986 or later or group led by researchers born before 1986).

The information required for an application to be evaluated will be as follows:

- Report of the Research Project according to the model provided .
- *Abbreviated Curriculum Vitae* (CVA-ISCI), automatically generated from the CVN editor (<http://cvn.fecyt.es/editor>) or from any institution certified in the standard

CVN of the FECYT that offers the CVA-ISCI service, of the principal investigator and the rest of the collaborators **(in English)**..

- Authorisation from the director of the healthcare centre where the Project is to be carried out in accordance with the model provided.
- Statutes of the beneficiary applicant entity.
- Power of attorney of the signatory of the entity.
- Registration of said entity in the corresponding register.
- Certificate of Declaration of Public Utility in the case of Associations.

The applications together with the corresponding Annexes will be submitted by the interested parties electronically within the period indicated on the www.BecasGileadInvestigacion.es website, from June 1st to June 30th.

The submission of any application after the established period will mean its exclusion from this procedure, and this fact will be reliably communicated to the applicant entity .

2. Validation of Proposals received

Once the call has closed, during the first week of July it will be verified that the applications submitted meet the requirements established by the Terms and Conditions of the call.

In the event that there are **applications that do not comply with the bases**, the applicant will be notified and an **allegation period of 10 calendar days will be opened**.

In the event that the **applications are submitted incomplete**, the applicant entity will also be notified of this, granting it a period of ten calendar days to proceed with its correction at the risk of being excluded from this call.

3. Procedure, evaluation Criteria and Competent Bodies for the evaluation of proposals .

3.1 Procedure

The evaluation of the projects received will be carried out by the Instituto de Salud Carlos III, which will act, independently and in accordance with the principles of transparency, objectivity, and equal treatment, in accordance with the following procedure.

For this Thirteenth Call, the Instituto de Salud Carlos III has brought the review process to the international level, as in the previous edition, and will include international reviewers, for this reason it is essential that the report and CVs are in English.

The research project proposals will undergo a two-phase review process.

The **first phase will consist of a scientific-technical review** of each project that will be carried out individually by at least two international experts.

These experts will be selected by the Instituto de Salud Carlos III and will confidentially and independently issue a review report on each proposal. Once the individual reports are analysed, a scientific-technical synthesis report will be prepared by independent experts.

The **second phase will consist of a panel review process** for all proposals by a Technical Review Board.

The Technical Review Board appointed by the ISCIII **will prepare a final report** for each proposal describing the most relevant aspects of the reviews carried out in the first phase and issue, in a consensus manner, a list of the proposals in order according to the score obtained using the review criteria set forth in the terms and conditions for the call.

3.2 Scientific-technical review criteria for the proposals:

a) Research team assessment:

Both the principal investigator and the rest of the team will be assessed: Academic record; curricular merits (publications, funding of research projects, experience, mobility, national and international collaborations and healthcare activity developed) and suitability of the candidates for the tasks to be carried out.

b) Project assesment:

The project will be assessed with regard to the following: quality, viability, relevance, interest, applicability and transfer; project capacity to improve disease prevention, diagnosis and treatment; impact; technology and outcome dissemination and transfer plan.

The review process is expected to be carried out by **four Technical Review Boards (TRB)** composed of national and international experts to assess the different research areas. Depending on the number of applications received, the number of technical committees could be adjusted to meet the needs.

These boards will be composed of a chair and a number of experts that will vary according to the number of proposals. The chair of each board will assign each proposal to **two reviewers for scientific-technical review from among experts unrelated to the board** and will likewise appoint, from among the board members, those responsible for preparing the synthesis reports.

All synthesis reports will be prepared by board members, and each board member will be assigned a similar number of proposals.

A board will be created to manage the review of proposals affected by **conflicts of interest** as a means to ensure the neutrality, transparency and objectivity of the process (“Technical Conflict of Interest Board”).

Proposals will be understood to have a conflict of interest and, therefore, will be managed by this board whenever a board member has a direct or indirect relationship or interest, whether personal (by virtue of a family bond), economic, scientific, educational training, in particular the following:

- When the proposal is sponsored by a grant applicant in which the reviewer is involved, whether as a result of a professional dependent relationship, or by virtue of any other form of direct or indirect assistance.
- When the proposed award could have some kind of financial impact for the reviewer.
- When the proposal could interfere with the scientific interests of the reviewer in question.

In general, explicit or potential conflicts of interest will be identified by the chairs of the two Technical Review Boards prior to the reviewer assignment process.

In any case, for the purpose of safeguarding neutrality and independence in the review process, the Instituto de Salud Carlos III will ensure that experts participating in the proposal review process sign the “Ethical Review Commitment” requiring that they abstain from reviewing proposals in which there is a conflict of interest. Hereunder they also agree to maintain absolute confidentiality of all information to which they have access and the entire review process.

4. Proposed Award

Once the proposals have been reviewed by the panel, the result of the review and the prioritized lists of project proposals will be sent to the Selection Board, licensed body, composed of the following:

- Subdirector General for the Review and Promotion of Research or the person who substitutes him/her.
- An official from the Subdirectorate General for the Review and Promotion of Research who will act as secretary.
- Chairs of the Technical Review Boards.

The decisions made by the Technical Review Boards cannot be appealed.

The Selection Board will confirm that the review process has been properly executed and, in view of the prioritized list of research project proposals and the budget allocated in the conditions, will prepare a report listing all proposals considered eligible, in particular, listing the fundable budget, according to criteria of maximum efficiency in the assignment of available financial resources. This report will be sent to GILEAD along with the meeting minutes, under conditions to ensure its confidentiality.

5. Grant Award and Notification to Grant Applicants

The Selection Committee will prepare an individual report per project detailing the acceptance/rejection of the application, as well as the most relevant aspects to highlight in the evaluation. These reports will be sent by the ISCIII to GILEAD, which is responsible for their inclusion on the website of the Gilead Biomedical Research Scholarship Program (BecasGileadInvestigacion@gilead.com). Each resulting report will be accessible to the corresponding researcher responsible for the project applying for the grant. In the event that the investigators request additional causes from GILEAD, it will be the ISCIII that will inform the investigators of the details included in the report. GILEAD will proceed to approve the granting of the grants based on the content of the Report-proposal prepared by the Selection Committee described above.

6. Signing of the Letter of Concession between GILEAD and the beneficiary applicant entity

After Receive the Letter of resolution, GILEAD will send to the Entity beneficiary applicant via email the Letter of Concession. This charter is intended to regulate the execution of the selected research project. The Concession Letter must be duly signed by the legal representative of the beneficiary entity before the start of the project.

By signing of the aforementioned Letter of Concession, the beneficiary applicant entity will assume the following obligations:

- a) Execute the project under the terms and deadlines described in the documentation submitted, without prejudice to the modifications imposed in terms of the eligible budget, by the resolution granting the aid itself.
- b) Notify GILEAD of any specific circumstance, duly justified, that implies changes in the technical or economic conditions taken into account for the granting of the aid and that could force a modification of the approved project. In this case, the changes must be requested before the end of the twenty-four-month period of execution of the project and will only be authorised if the objectives or essential aspects of the project are not distorted . In the event that you need to extend the project execution period, you must send an email to becasgileadinvestigación@gilead.com informing you of the new end date of the project and the justification. If the extension you are requesting is less than or equal to 12 months, you will not need to receive approval from the Gilead Scholarship Review Committee, this extension being already accepted with the sending of the informative email; but in the event that this extension is longer than 12 months, it must also be communicated and justified, and must be evaluated by the Committee, the authorization of these extensions being exceptional.
- c) Declare that they have not obtained funds or sources of financing for the project other than those declared in their application.
- d) Notify GILEAD of the award of any other subsidy, aid or funding source that it could receive for the same project after the agreement has been signed. This fact could lead to a modification in the fundable budget awarded, if the finally funded amount received were to require it under the provisions of Condition Three hereof, it being necessary to refund the excess amount received.
- e) Perform regular follow-up of project development to ensure that it meets the work plan proposed in the application. A final report must be prepared by the project's principal investigator to provide a detailed description of the objectives and results achieved in the research and **must be submitted by email to the address BecasGileadInvestigacion@gilead.es** within 30 calendar days after the end of the project execution deadline. The agreement may also allow such results to be presented at a personal meeting to which they may be called along with other organizations awarded grants hereunder.
- f) Include, in any publication or medium by which the content of the research project is disseminated, an express reference to GILEAD's participation in its funding through the Gilead Biomedical Research Grants Program: specifically, the following text should be included next to the Gilead logo: "***With the collaboration of the Gilead Biomedical Research Grants Program (GLDXX-XXX)***". However, the beneficiary applicant entity undertakes to notify the Company, sufficiently in advance, of any act of public communication of the results obtained through the research project that is the subject of aid within the framework of this call.

All this is understood, without prejudice to the ownership of the intellectual and industrial

property rights that may arise from the execution of the project, which will be owned by its authors in the terms provided for in the applicable legislation. However, the authors shall expressly consent to GILEAD citing them in this capacity both on its website and, where appropriate, in any other publication of the Company.

- g) Submit an economic report confirming that the budgeted expenses have been made as requested. You must keep a justified copy of the expenses corresponding to the items that make up the approved eligible budget for the execution of the research project in the event that GILEAD so requires. To this end, the provision of invoices accrediting the expenses and payments made, as well as any other documentation that could be used to demonstrate the payment by the beneficiary applicant entity in accordance with commercial practice, may be required.
- h) Keep the supporting documentation justifying both the payment of the aid by GILEAD and the application of the funds received for a period of six years from its presentation for the purposes of possible verification and control actions.
- i) To actively collaborate with GILEAD in the event that it is necessary to prove to the Tax Administration any point relating to the signing and compliance with the Letter of Concession in order to facilitate the application of the tax regime provided for in Article 25 of Law 49/2002, of 23 December, with respect to the amount of aid provided by GILEAD for the financing of the research activities described therein.
- j) To return all or part of the amount of the aid received in the event of not executing, in whole or in part, the funded research project or not justifying its execution in the terms described in these Terms and Conditions.

7. Grant Payment

The grant approved by GILEAD will be paid as a lump sum to the grant recipient within 30 calendar days as of date on which the collaboration agreement alluded to in the preceding point is signed.

Payment will be made by bank transfer to the account designated by the beneficiary applicant entity in its application or, where appropriate, in the Letter itself.

Follow up and disclosure of results by GILEAD:

GILEAD reserves the right to perform regular follow-up on the progress of the research projects by the grant applicants. A final report of the research project shall be submitted to GILEAD the month after the date on which it ends.

The results and conclusions reached in this report will be subject to presentation at a public meeting convened for such purpose by GILEAD, which may require the participation of the principal investigators (or, where applicable, of some other member of the research team) responsible for execution of the respective research projects.